As 2025 comes to a close, one thing is clear for CONNEQT Health: this was a year of delivery.
Across both Consumer and Enterprise, our focus was on executing against decades of clinical research and validation, bringing arterial health out of specialized settings and into scalable, regulated, and commercially viable use. The year was defined by disciplined progress across regulation, product, partnerships, and adoption.
Measure what matters
Save 20% on checkout with code VITALITY
The global longevity and wellness economy is estimated at approximately $6.3 trillion, spanning diagnostics, therapeutics, digital health, and prevention. Yet despite that scale, arterial health, one of the most influential drivers of long-term outcomes, has remained largely inaccessible outside specialized clinical environments. This gap represents one of the largest unclaimed opportunities in preventive health: translating arterial intelligence into actionable, scalable insight.
This year, we took meaningful steps toward closing that gap. The emphasis was not on short-term wins, but on laying durable foundations that became clearer quarter by quarter.
Q1: Consumer Momentum and Market Readiness
The year began with strong momentum on the consumer side of the business.
Following notable interest from a waitlist of more than 20,000 individuals, the CONNEQT Pulse officially launched for sale in the U.S. in January, marking our transition from pre-launch anticipation to commercial availability. Early demand reinforced something we had long believed: consumers are increasingly aware that traditional blood pressure cuffs provide only part of the cardiovascular picture.
In March, we introduced On-Demand Arterial Health Assessments, giving users flexible access to clinically grounded insights without requiring continuous monitoring. This milestone reinforced an important lesson early in the year: meaningful engagement comes not from volume alone, but from offering the right level of insight at the right time.
Behind the scenes, our teams focused heavily on operational readiness, refining onboarding, education, fulfillment, and customer support. These investments ensured that as adoption increased, the experience remained consistent, credible, and approachable.
While Q1 leaned heavily toward Consumer, Enterprise conversations continued to mature in parallel, setting the stage for more formal clinical integrations later in the year.
Q2: Expanding Clinical Utility and Platform Integration
The second quarter marked a meaningful expansion of CONNEQT Health’s clinical footprint.
On the Enterprise side, Q2 saw the integration of the Cardiology Report into SphygmoCor XCEL, enabling a consumption-based Arterial Health Assessment model. This shift was pivotal. By aligning advanced arterial analytics with a scalable, usage-based framework, CONNEQT began lowering barriers for clinics and researchers to incorporate arterial assessments into routine workflows.
Rather than centering the model on device ownership, this approach emphasized clinical utility, flexibility, and integration, principles that continue to guide our enterprise strategy.
On the Consumer side, Q2 brought Apple Health integration, allowing Pulse users to place systolic and diastolic blood pressure readings alongside activity, sleep, and other wellness data. This reinforced arterial health as a foundational signal, not a standalone datapoint, and supported more holistic interpretation of cardiovascular trends.
Q2 also delivered a significant regulatory milestone. In May, the Pulse received TGA approval in Australia, expanding future commercialization opportunities in a strategically important market and underscoring the global credibility of our validation framework.
As Dr. Carmel McEniery, PhD, Senior Research Associate at the University of Cambridge and a leading arterial health researcher, has noted, “The CONNEQT Pulse is an easy-to-use, all-in-one device that provides detailed insights into our cardiovascular health.” Her work underscores why bringing rigorously validated arterial metrics into more accessible formats is essential for advancing both research and care.
Q3: Scaling Adoption and Deepening Clinical Trust
By Q3, our focus shifted from integration to adoption and trust.
Enterprise pilots expanded across primary care and sports clinics, offering valuable insight into how arterial health assessments function across different care models, from early risk stratification to longitudinal monitoring.
Clinician feedback during this period was particularly instructive. Reporting formats, education tools, and workflows continued to evolve, reinforcing our view that validation is not a single milestone, but an ongoing dialogue between technology, clinicians, and outcomes.
On the Consumer side, engagement remained steady, supported by continued education around arterial stiffness, central blood pressure, and why these functional metrics often change years before symptoms or imaging findings emerge. As users began to recognize patterns rather than isolated readings, arterial health became more actionable and less abstract.
Q4: Platform Maturity and Ecosystem Expansion
The final quarter of 2025 brought several of the year’s most visible milestones and marked a shift from product-led growth toward platform maturity.
On the Consumer side, we launched Care+, which introduced in-app monetization and validated a recurring subscription model. Early performance, including a 4 percent conversion rate in the first month and 70 percent annual plan adoption, confirmed that users see sustained value in deeper, ongoing arterial insights. Care+ now serves as a foundational growth engine as we move forward.
Q4 also marked the rollout of Google Fit integration, expanding interoperability and ensuring users can access arterial health insights across both major mobile ecosystems.
Commercially, CONNEQT is on track to close the year with more than USD $1.3 million (AUD $2 million) in Pulse sales, reflecting growing confidence in the category and the platform itself.
On the Enterprise side, deeper collaborations accelerated in Q4, with increased interest in Biomarker-as-a-Service models and the broader CONNEQT Arterial Intelligence Platform. These developments reflect a broader market shift toward scalable, validated approaches to early detection of cardiovascular risk across research, clinical, and population health settings.
Dr. Michael Twyman, MD, Founder of Apollo Cardiology, echoed this perspective, noting, “This device is going to be a game changer for many people,” and emphasizing the importance of early insight in reshaping how patients engage with their long-term cardiovascular health.
That emphasis on early awareness and patient engagement was reinforced by Dr. J. Perez, Cardiologist, who highlighted the “quality of the patient-facing educational material” and the ability for patients to track their own metrics and engage meaningfully with their cardiovascular health. This approach can fundamentally change how people relate to prevention.
Looking Ahead
As I reflect on the progress we made in 2025, I’m struck by how much of this year was about turning intention into execution. We moved from anticipation to delivery, from validation to adoption, and from individual milestones to a platform that is beginning to scale in meaningful ways.
At the same time, this work underscores the significant opportunities that remain. Expanding access to arterial intelligence, deepening clinical trust, and embedding prevention earlier in everyday health decisions will require continued focus and collaboration. We are committed to building responsibly, grounded in evidence, and alongside the clinicians, partners, and customers who share that goal.
Thank you for the trust you place in CONNEQT Health and for being part of this journey. I’m looking forward to what we will continue to build together in the year ahead.
Craig Cooper
CEO, CONNEQT Health
